← 治験一覧に戻る
進行性または転移性固形腫瘍を有する日本人被験者におけるバルリチニブの研究
基本情報
- NCT ID
- NCT03082053
- ステータス
- 完了
- 試験のフェーズ
- 第1相
- 試験タイプ
- 介入
- 目標被験者数
- 24
- 治験依頼者名
- ASLAN Pharmaceuticals
概要
The purpose of this study is to explore safety and efficacy of varlitinib administered as monotherapy in Japanese subjects with advanced or metastatic solid tumors, and administered as combination with capecitabine in Japanese subjects with advanced or metastatic biliary tract cancer. Also to evaluate pharmacokinetics (PK) of varlitinib, capecitabine and its metabolite.
対象疾患
Advanced or Metastatic Biliary Tract CancerAdvanced or Metastatic Solid Tumors
介入
varlitinib(DRUG)
capecitabine(DRUG)
依頼者（Sponsor）
Aslan(OTHER)
実施施設 (1)
ASLAN Selected sites
Tokyo, Japan